Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01919697 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,370
- Enrollment target
NCT01919697 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 2,370 participants.
The verdict
NCT01919697, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,370 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).
Interventions
- DRUG Plecanatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,370 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01919697
The ClinicalTrials.gov registry entry for NCT01919697 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,370 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Plecanatide is the first listed.
NCT01919697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01919697 about?
NCT01919697 is a clinical study titled "Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)". This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).
What is the current status of trial NCT01919697?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,370 participants. The study started on 2013-08. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01919697?
The interventions under investigation include: Plecanatide (DRUG).
Who is sponsoring clinical trial NCT01919697?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.